Nasdaq warns Cardima over listing requirements
This article was originally published in Clinica
Executive Summary
Cardima's ailing fortunes could soon spell a delisting from the US stock exchange. The Fremont, California-based company has received written notice from Nasdaq that, following a review of its third-quarter results for the period ended September 30 2004 and of its listed securities' market value, the firm had fallen below the minimum requirements to remain eligible for listing on the market.